Risk factors for glucocorticoid induced osteoporosis in young adults
IntroductionGlucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age....
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1528962/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321083838136320 |
|---|---|
| author | Helena Florez Josep Lluis Carrasco Martina Barberá José Hernández-Rodríguez Africa Muxi Anastasia Mocritcaia Sergio Prieto-González Maria C. Cid Ana Monegal Núria Guañabens Pilar Peris |
| author_facet | Helena Florez Josep Lluis Carrasco Martina Barberá José Hernández-Rodríguez Africa Muxi Anastasia Mocritcaia Sergio Prieto-González Maria C. Cid Ana Monegal Núria Guañabens Pilar Peris |
| author_sort | Helena Florez |
| collection | DOAJ |
| description | IntroductionGlucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age. The aim of the study was to analyze if factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF) differ according to age.Methods127 patients on chronic glucocorticoid (GC) treatment were analyzed, including GC doses and duration, disease activity, FF, anthropometric data, bone metabolism parameters (including sex steroids), bone mineral density, trabecular bone score, and radiologic vertebral fractures; defining GIOP as densitometric osteoporosis and/or FF. Young subjects (<50 years old) were compared with those ≥50 years for risk factors of GIOP and FF.ResultsGIOP prevalence was similar in both age groups: <50 (n=36) 44.4% vs. 46.1% ≥50 years (n=91). Five subjects <50 (13.9%) and 30 ≥50 years (33%) presented FF (p=0.046). Having a higher body mass index (BMI), disease activity was a differential risk factor for FF in young subjects, whereas hypogonadism was a risk factor independent of age.ConclusionsMore than 40% of young subjects on chronic GC therapy had GIOP. A higher BMI and disease activity and particularly, hypogonadism seem to be factors related to FF development in these subjects. Evaluation of these risk factors can improve the identification of young subjects at increased risk of fracture. |
| format | Article |
| id | doaj-art-9a0590778d96463d9869db6a5aa09dc9 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-9a0590778d96463d9869db6a5aa09dc92025-08-20T03:49:50ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-07-011610.3389/fendo.2025.15289621528962Risk factors for glucocorticoid induced osteoporosis in young adultsHelena Florez0Josep Lluis Carrasco1Martina Barberá2José Hernández-Rodríguez3Africa Muxi4Anastasia Mocritcaia5Sergio Prieto-González6Maria C. Cid7Ana Monegal8Núria Guañabens9Pilar Peris10Metabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainBiostatistics, Department of Basic Clinical Practice, University of Barcelona, Barcelona, SpainBiostatistics, Department of Basic Clinical Practice, University of Barcelona, Barcelona, SpainVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainDepartment of Nuclear Medicine, Hospital Clinic, University of Barcelona, Barcelona, SpainMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainMetabolic Bone Diseases Unit. Department of Rheumatology. Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainIntroductionGlucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age. The aim of the study was to analyze if factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF) differ according to age.Methods127 patients on chronic glucocorticoid (GC) treatment were analyzed, including GC doses and duration, disease activity, FF, anthropometric data, bone metabolism parameters (including sex steroids), bone mineral density, trabecular bone score, and radiologic vertebral fractures; defining GIOP as densitometric osteoporosis and/or FF. Young subjects (<50 years old) were compared with those ≥50 years for risk factors of GIOP and FF.ResultsGIOP prevalence was similar in both age groups: <50 (n=36) 44.4% vs. 46.1% ≥50 years (n=91). Five subjects <50 (13.9%) and 30 ≥50 years (33%) presented FF (p=0.046). Having a higher body mass index (BMI), disease activity was a differential risk factor for FF in young subjects, whereas hypogonadism was a risk factor independent of age.ConclusionsMore than 40% of young subjects on chronic GC therapy had GIOP. A higher BMI and disease activity and particularly, hypogonadism seem to be factors related to FF development in these subjects. Evaluation of these risk factors can improve the identification of young subjects at increased risk of fracture.https://www.frontiersin.org/articles/10.3389/fendo.2025.1528962/fullglucocorticoid-induced osteoporosishypogonadismyoung patientsfragility fracturerisk factors |
| spellingShingle | Helena Florez Josep Lluis Carrasco Martina Barberá José Hernández-Rodríguez Africa Muxi Anastasia Mocritcaia Sergio Prieto-González Maria C. Cid Ana Monegal Núria Guañabens Pilar Peris Risk factors for glucocorticoid induced osteoporosis in young adults Frontiers in Endocrinology glucocorticoid-induced osteoporosis hypogonadism young patients fragility fracture risk factors |
| title | Risk factors for glucocorticoid induced osteoporosis in young adults |
| title_full | Risk factors for glucocorticoid induced osteoporosis in young adults |
| title_fullStr | Risk factors for glucocorticoid induced osteoporosis in young adults |
| title_full_unstemmed | Risk factors for glucocorticoid induced osteoporosis in young adults |
| title_short | Risk factors for glucocorticoid induced osteoporosis in young adults |
| title_sort | risk factors for glucocorticoid induced osteoporosis in young adults |
| topic | glucocorticoid-induced osteoporosis hypogonadism young patients fragility fracture risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1528962/full |
| work_keys_str_mv | AT helenaflorez riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT joseplluiscarrasco riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT martinabarbera riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT josehernandezrodriguez riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT africamuxi riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT anastasiamocritcaia riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT sergioprietogonzalez riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT mariaccid riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT anamonegal riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT nuriaguanabens riskfactorsforglucocorticoidinducedosteoporosisinyoungadults AT pilarperis riskfactorsforglucocorticoidinducedosteoporosisinyoungadults |